Status:
RECRUITING
A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
Lead Sponsor:
Mayo Clinic
Conditions:
Hematopoietic and Lymphatic System Neoplasm
Acute Lymphobkastic Leukemia
Eligibility:
All Genders
1+ years
Brief Summary
This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.
Detailed Description
PRIMARY OBJECTIVE: I. To determine incidence of patients who develop hyperammonemia secondary to recombinant Erwinia asparaginase. II. To characterize patients at risk for hyperammonemia secondary t...
Eligibility Criteria
Inclusion
- Followed by pediatric hematology/oncology
- Receiving recombinant Erwinia asparaginase for treatment of malignancy
Exclusion
- Patients \< 1 year of age
- Patients who have previously received recombinant Erwinia asparaginase within the past two weeks
Key Trial Info
Start Date :
November 2 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06600659
Start Date
November 2 2023
End Date
December 1 2026
Last Update
September 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905